{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:01:52Z","timestamp":1791396112056,"version":"4.3.3"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002066","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002066","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Co-administration of AS01E-adjuvanted respiratory syncytial virus vaccine (adjuvanted RSVPreF3) and AS01B-adjuvanted recombinant herpes zoster subunit vaccine (RZV), although not contraindicated, has not been previously studied in clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This phase III, open-label, randomized (1:1) trial evaluated the immunogenicity, safety, and reactogenicity of adjuvanted RSVPreF3 when co-administered with RZV in \u226550-year-olds. The 2 vaccines were either co-administered at visit 1 (day [D] 1; Co-Ad), or were given sequentially, 1 month apart (RZV dose 1 at D1, adjuvanted RSVPreF3 at D31; Control). All participants received RZV dose-2 at D61. Non-inferiority of humoral immune responses was demonstrated if 95% confidence interval (CI) upper limits for geometric mean RSV-A\/B neutralizing titers (GMT) and varicella-zoster virus anti-glycoprotein E (anti-gE) antibody concentration (GMC) ratios (Control\/Co-Ad) were \u22641.5. Safety and reactogenicity were secondary endpoints.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 530 participants (Co-Ad = 265; Control = 265) were vaccinated. Neutralizing GMT ratios for RSV-A (1.1 [95% CI = 1.0\u20131.4]) and RSV-B (1.0 [0.8\u20131.2]), and anti-gE antibody GMC ratio (1.2 [1.1\u20131.4]) met non-inferiority criteria. Within 7 days post-vaccination, 71.7% (Co-Ad: post-RZV dose 1 and adjuvanted RSVPreF3; grade [Gr] 3 = 3.9%), 58.5% (Control: post-RZV dose 1; Gr3 = 1.9%), and 47.8% (Control: post-adjuvanted RSVPreF3; Gr3 = 1.2%) of participants reported solicited administration-site adverse events (AEs). Post-visit 1, 73.6% (Gr3 = 9.3%) of Co-Ad and 60.4% (Gr3 = 6.2%) of control participants reported solicited systemic AEs. Within 30 days post-any vaccination, 23.4% (Gr3 = 0.8%) of Co-Ad and 30.2% (Gr3 = 1.1%) of control participants reported unsolicited AEs. No fatal or related serious AEs were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Immunogenicity, reactogenicity, and safety data support the co-administration of adjuvanted RSVPreF3 and RZV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trials Registration<\/jats:title>\n                    <jats:p>NCT05966090.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciag208","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T11:44:46Z","timestamp":1776253486000},"page":"e578-e588","source":"Crossref","is-referenced-by-count":3,"title":["Immunogenicity and Safety of the Adjuvanted Respiratory Syncytial Virus Prefusion F Protein-Based Vaccine When Co-administered With the Adjuvanted Recombinant Herpes Zoster Subunit Vaccine in Adults \u2265 50 Years of Age"],"prefix":"10.1093","volume":"83","author":[{"given":"Jean-Fran\u00e7ois","family":"Roussy","sequence":"first","affiliation":[{"name":"DIEX Research , Qu\u00e9bec, Qu\u00e9bec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Dennis","sequence":"additional","affiliation":[{"name":"DELRIGHT Research , New Orleans, Louisiana ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil K","family":"Gupta","sequence":"additional","affiliation":[{"name":"Albion Finch Medical Center , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garry","family":"Wallace","sequence":"additional","affiliation":[{"name":"Dawson Clinical Research , Guelph, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6830-3532","authenticated-orcid":false,"given":"Alexander","family":"Abitbol","sequence":"additional","affiliation":[{"name":"LMC Healthcare\/Centricity Research , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Aggarwal and Associates , Brampton, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph G","family":"Surber","sequence":"additional","affiliation":[{"name":"Centricity Research Talbotton , Columbus, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore","family":"Lee","sequence":"additional","affiliation":[{"name":"Headlands Research , Orlando, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1572-3248","authenticated-orcid":false,"given":"Brian A","family":"Smith","sequence":"additional","affiliation":[{"name":"CCT Research , Versailles, Kentucky ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"G\u00e9rard","sequence":"additional","affiliation":[{"name":"GSK , Rixensart ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiwot Amare","family":"Hailemariam","sequence":"additional","affiliation":[{"name":"GSK , Wavre ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Pierre","family":"David","sequence":"additional","affiliation":[{"name":"GSK , Wavre ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana M","family":"Jastorff","sequence":"additional","affiliation":[{"name":"GSK , Wavre ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3808-8767","authenticated-orcid":false,"given":"Marie","family":"Van der Wielen","sequence":"additional","affiliation":[{"name":"GSK , Wavre ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"2026100713415895200_ciag208-B1","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1093\/cid\/ciab595","article-title":"Incidence of respiratory syncytial virus infection among hospitalized adults, 2017\u20132020","volume":"74","author":"Branche","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026100713415895200_ciag208-B2","doi-asserted-by":"crossref","first-page":"793","DOI":"10.15585\/mmwr.mm7229a4","article-title":"Use of respiratory syncytial virus vaccines in older adults: recommendations of the advisory committee on immunization practices - United States, 2023","volume":"72","author":"Melgar","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026100713415895200_ciag208-B3","doi-asserted-by":"crossref","first-page":"l5021","DOI":"10.1136\/bmj.l5021","article-title":"Respiratory syncytial virus infection in adults","volume":"366","author":"Nam","year":"2019","journal-title":"BMJ"},{"key":"2026100713415895200_ciag208-B4","doi-asserted-by":"crossref","first-page":"e158","DOI":"10.1093\/cid\/ciaa730","article-title":"Respiratory syncytial virus-associated hospitalizations among adults with chronic medical conditions","volume":"73","author":"Prasad","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026100713415895200_ciag208-B5","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.idc.2017.07.016","article-title":"Herpes zoster in the older adult","volume":"31","author":"John","year":"2017","journal-title":"Infect Dis Clin North Am"},{"key":"2026100713415895200_ciag208-B6","doi-asserted-by":"crossref","first-page":"ofaa005","DOI":"10.1093\/ofid\/ofaa005","article-title":"Risk factors for herpes zoster infection: a meta-analysis","volume":"7","author":"Marra","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2026100713415895200_ciag208-B7","doi-asserted-by":"crossref","first-page":"ofae535","DOI":"10.1093\/ofid\/ofae535","article-title":"Burden of herpes zoster in individuals with chronic conditions in the Republic of Korea: a nationwide population-based database study","volume":"11","author":"Chen","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026100713415895200_ciag208-B8","volume-title":"SARS, MERS and other viral lung infections","author":"Jha","year":"2016"},{"key":"2026100713415895200_ciag208-B9","doi-asserted-by":"crossref","first-page":"e13031","DOI":"10.1111\/irv.13031","article-title":"Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: a systematic literature review and meta-analysis","volume":"17","author":"Savic","year":"2023","journal-title":"Influenza Other Respir Viruses"},{"issue":"RR-5","key":"2026100713415895200_ciag208-B10","first-page":"1","article-title":"Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"57","author":"Harpaz","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"2026100713415895200_ciag208-B11","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41541-023-00757-0","article-title":"Healthy ageing: herpes zoster infection and the role of zoster vaccination","volume":"8","author":"Curran","year":"2023","journal-title":"NPJ Vaccines"},{"key":"2026100713415895200_ciag208-B12"},{"key":"2026100713415895200_ciag208-B13"},{"key":"2026100713415895200_ciag208-B14"},{"key":"2026100713415895200_ciag208-B15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3390\/vaccines13020097","article-title":"Development, current status, and remaining challenges for respiratory syncytial virus vaccines","volume":"13","author":"Anastassopoulou","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"2026100713415895200_ciag208-B16","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S2213-2600(24)00255-8","article-title":"Respiratory syncytial virus infections in adults: a narrative review","volume":"12","author":"Wildenbeest","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2026100713415895200_ciag208-B17","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s40121-025-01135-0","article-title":"Optimal timing of vaccination: a narrative review of integrating strategies for COVID-19, influenza, and respiratory syncytial virus","volume":"14","author":"Bonanni","year":"2025","journal-title":"Infect Dis Ther"},{"key":"2026100713415895200_ciag208-B18","doi-asserted-by":"crossref","first-page":"696","DOI":"10.15585\/mmwr.mm7332e1","article-title":"Use of respiratory syncytial virus vaccines in adults aged \u226560 years: updated recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2024","volume":"73","author":"Britton","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026100713415895200_ciag208-B19"},{"key":"2026100713415895200_ciag208-B20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12931-022-02305-1","article-title":"Risk factors for herpes zoster: should people with asthma or COPD be vaccinated?","volume":"24","author":"Safonova","year":"2023","journal-title":"Respir Res"},{"key":"2026100713415895200_ciag208-B21","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1080\/14760584.2021.1956906","article-title":"A practitioner's guide to the recombinant zoster vaccine: review of national vaccination recommendations","volume":"20","author":"Parikh","year":"2021","journal-title":"Expert Rev Vaccines"},{"key":"2026100713415895200_ciag208-B22"},{"key":"2026100713415895200_ciag208-B23","doi-asserted-by":"crossref","first-page":"80","DOI":"10.15585\/mmwr.mm7103a2","article-title":"Use of recombinant zoster vaccine in immunocompromised adults aged \u226519 years: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2022","volume":"71","author":"Anderson","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026100713415895200_ciag208-B24","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1007\/s40121-024-00985-4","article-title":"Randomized, open-label phase 3 study evaluating immunogenicity, safety, and reactogenicity of RSVPreF3 OA coadministered with FLU-QIV-HD in adults aged\u226565","volume":"13","author":"Buynak","year":"2024","journal-title":"Infect Dis Ther"},{"key":"2026100713415895200_ciag208-B25","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1093\/cid\/ciad786","article-title":"Immunogenicity, reactogenicity, and safety of AS01E-adjuvanted respiratory syncytial virus (RSV) prefusion F protein-based candidate vaccine (RSVPreF3 OA) when co-administered with a seasonal quadrivalent influenza vaccine in older adults: results of a phase 3, open-label, randomized controlled trial","volume":"83","author":"Chandler","year":"2026","journal-title":"Clin Infect Dis"},{"key":"2026100713415895200_ciag208-B26","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/cid\/ciae365","article-title":"Safety and immunogenicity of respiratory syncytial virus prefusion F protein vaccine when co-administered with adjuvanted seasonal quadrivalent influenza vaccine in older adults: a phase 3 randomized trial","volume":"79","author":"Clark","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026100713415895200_ciag208-B27","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/j.vaccine.2024.02.035","article-title":"Co-administration of the adjuvanted recombinant zoster vaccine with other adult vaccines: an overview","volume":"42","author":"Ali","year":"2024","journal-title":"Vaccine"},{"key":"2026100713415895200_ciag208-B28"},{"key":"2026100713415895200_ciag208-B29"},{"key":"2026100713415895200_ciag208-B30"},{"key":"2026100713415895200_ciag208-B31","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1016\/j.vaccine.2018.05.110","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults \u226550\u202fyears of age: a randomized trial","volume":"36","author":"Mar\u00e9chal","year":"2018","journal-title":"Vaccine"},{"key":"2026100713415895200_ciag208-B32","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jinf.2021.12.033","article-title":"The adjuvanted recombinant zoster vaccine co-administered with the 13-valent pneumococcal conjugate vaccine in adults aged \u226550 years: a randomized trial","volume":"84","author":"Min","year":"2022","journal-title":"J Infect"},{"key":"2026100713415895200_ciag208-B33","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1093\/cid\/ciad361","article-title":"No immunological interference or safety concerns when adjuvanted recombinant zoster vaccine is coadministered with a Coronavirus Disease 2019 mRNA-1273 booster vaccine in adults aged 50 years and older: a randomized trial","volume":"77","author":"Naficy","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026100713415895200_ciag208-B34","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/infdis\/jix481","article-title":"Immunogenicity and safety of an adjuvanted herpes zoster subunit vaccine coadministered with seasonal influenza vaccine in adults aged 50 years or older","volume":"216","author":"Schwarz","year":"2017","journal-title":"J Infect Dis"},{"key":"2026100713415895200_ciag208-B35","doi-asserted-by":"crossref","first-page":"5877","DOI":"10.1016\/j.vaccine.2019.08.001","article-title":"The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged \u226550 years: a randomized trial","volume":"37","author":"Strezova","year":"2019","journal-title":"Vaccine"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciag208\/68188540\/ciag208.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/83\/3\/e578\/68188540\/ciag208.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/83\/3\/e578\/68188540\/ciag208.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:42:07Z","timestamp":1791394927000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/83\/3\/e578\/8665042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,4,29]]},"published-print":{"date-parts":[[2026,10,7]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciag208","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9,15]]},"published":{"date-parts":[[2026,4,29]]}}}